Compare

Two terms, side by side

Pick any two terms to see definitions, context, pitfalls, and sources in parallel.

Investment & Finance

Royalty Financing

In one line

Non-dilutive capital exchanged for a royalty (typically a percentage of revenue) on a defined product or product family, usually with a capped multiple of invested capital.

Definition

Royalty financing provides upfront capital in exchange for a contractual royalty stream — typically a percentage of net product revenue — until a defined cap (commonly 1.5-3x the financed amount) is reached. In MedTech and the adjacent life-sciences market, dedicated royalty funds (Royalty Pharma, HealthCare Royalty Partners, XOMA) underwrite these structures against products with established revenue or imminent launch. The structure is non-dilutive and typically has no equity, board, or governance rights.

Why it matters

Royalty financing is increasingly used by MedTech companies as bridge capital between approval and profitability, or as a partial monetization of a non-core product line. Cost of capital is generally 12-18% IRR equivalent — cheaper than equity but more expensive than venture debt.

Common pitfalls

•Stacking royalty financing on top of venture debt without modeling combined cash impact at low-revenue scenarios.
•Underestimating reporting and audit obligations to the royalty financier.

Sources

BIO — Non-Dilutive Funding Resources · BIO
SEC EDGAR — Royalty Pharma 10-K filings · SEC EDGAR
PitchBook - MedTech Coverage · PitchBook

Open full page

Select term B to compare.

Why compare MedTech terms side by side?

MedTech terminology is full of pairs that look interchangeable but carry very different regulatory, clinical, and commercial consequences. Picking the wrong framework, pathway, or standard early in a project can add months to a submission, invalidate clinical evidence, or trigger an audit finding. Side-by-side comparison is the fastest way to surface those differences before they become costly mistakes.

Each comparison on this page pulls from the same vendor-neutral, sourced definitions used throughout the MedTech Terms glossary. You see the one-line summary, the formal definition, why it matters in practice, common pitfalls, and the primary sources (FDA guidance, EU MDR/IVDR articles, ISO/IEC standards, MDCG documents, IMDRF principles) that back each entry. That makes the comparison defensible in regulatory strategy memos, design reviews, and submission narratives.

Common comparison patterns

Regulatory pathway choice - 510(k) vs PMA, 510(k) vs De Novo, Abbreviated vs Special 510(k).
Quality systems - QSR vs ISO 13485, QMSR vs QSR.
Software classification - SaMD vs SiMD, Locked vs adaptive AI.
EU frameworks - MDR vs IVDR, CE Mark vs UKCA.
Cybersecurity artifacts - SPDX vs CycloneDX SBOM, CVE vs CVSS.
Post-market actions - Recall vs field action, Removal vs correction.

How to use this tool

Pick term A and term B from the dropdowns, or click a preset above. The URL updates with both slugs so you can bookmark or share the exact comparison with a colleague, a notified body reviewer, or your regulatory consultant. Click Open full page on either side for the complete entry, including FAQs, related terms, and the full citation list. If you are not sure which term to start with, browse the Categories view or the A-Z index.

MedTech Terms is a vendor-neutral community resource sponsored by Blue Goat Cyber. Definitions are written for educational use and are not legal or regulatory advice.